Home|Journals|Articles by Year|Audio Abstracts
 

-

IJPRT. 2018; 8(2): 27-31


Pharmacovigilance system and the future challenges in India-A Perspective

*SANDHYA JAIN*, 1DR VIKAS JAIN, 2RADHA SHARMA.




Abstract

PVPI is the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of medications, biological products, blood products, herbals, vaccines, medical device, traditional and complementary medicines with a view to identifying new information about hazards associated with products and preventing harm to patients. This article provides a brief overview about the current situation and the future challenges of pharmacovigilance in India. The importance of implementing proper pharmacovigilance in the Indian scenario has been analysed the first recognised attempt to start pharmacovigilance activities in India dates back to 1986, when a formal Adverse Drug Reaction (ADR) monitoring system with 12 regional centres for a population of 50 million each, was proposed. However, the system did not come into existence. In 1997, India joined the World Health Organization’s ADR Monitoring Programme based in Uppsala, Sweden. The Uppsala Monitoring Centre (UMC) maintains an international database of suspected adverse drug reaction reports from all over the world to support good decision-making regarding the benefits and risks of treatment options for patients taking medicines

Key words: Adverse Drug Reaction (ADR), Uppsala Monitoring Centre (UMC), pharmacovigilance programme in India PVP






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.